|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/30 | |
| C07K 16/40 | |||
| A61K 39/00 |
| (11) | Number of the document | 3134439 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15720854.7 |
| Date of filing the European patent application | 2015-04-21 | |
| (97) | Date of publication of the European application | 2017-03-01 |
| (45) | Date of publication and mention of the grant of the patent | 2018-12-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/026806 |
| Date | 2015-04-21 |
| (87) | Number | WO 2015/164330 |
| Date | 2015-10-29 |
| (30) | Number | Date | Country code |
| 201461982098 P | 2014-04-21 | US | |
| 201462004496 P | 2014-05-29 | US |
| (72) |
BRAKE, Rachael L., US
BURKHARDT, Anne L., US
HE MCDOUGALL, Helen D., US
KANNAN, Karuppiah, US
THEISEN, Matthew, US
TIRRELL, Stephen M., US
|
| (73) |
Millennium Pharmaceuticals, Inc.,
40 Landsdowne Street, Cambridge, MA 02139,
US
|
| (54) | ANTI-PSYK ANTIBODY MOLECULES AND USE OF SAME FOR SYK-TARGETED THERAPY |
| ANTI-PSYK ANTIBODY MOLECULES AND USE OF SAME FOR SYK-TARGETED THERAPY |